Zealand Pharma(ZEAL) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -5.16丹麦克朗 [[[0,"-5.78"],[1,"-12.66"],[2,"-17.26"],[3,"-23.75"],[4,"-5.16"]],[[0,"2021\u4e00\u5b63\u62a5"],[1,"2021\u4e2d\u62a5"],[2,"2021\u4e09\u5b63\u62a5"],[3,"2021\u5e74\u62a5"],[4,"2022\u4e00\u5b63\u62a5"]],"\u4e39\u9ea6\u514b\u6717"] 每股收益单位：丹麦克朗查看明细>>	归母净利润： -2.23亿丹麦克朗同比增长7.99% [[[0,"-2.42"],[1,"-5.39"],[2,"-7.38"],[3,"-10.18"],[4,"-2.23"]],[[0,"2021\u4e00\u5b63\u62a5"],[1,"2021\u4e2d\u62a5"],[2,"2021\u4e09\u5b63\u62a5"],[3,"2021\u5e74\u62a5"],[4,"2022\u4e00\u5b63\u62a5"]],"\u4ebf\u4e39\u9ea6\u514b\u6717"] 净利润单位：亿丹麦克朗查看明细>>	每股净资产： 16.26丹麦克朗 [[[0,"38.31"],[1,"31.85"],[2,"27.21"],[3,"21.26"],[4,"16.26"]],[[0,"2021\u4e00\u5b63\u62a5"],[1,"2021\u4e2d\u62a5"],[2,"2021\u4e09\u5b63\u62a5"],[3,"2021\u5e74\u62a5"],[4,"2022\u4e00\u5b63\u62a5"]],"\u4e39\u9ea6\u514b\u6717"] 每股净资产单位：丹麦克朗查看明细>>	净资产收益率ROE(平均)： -27.22% [[[0,"-94.40"],[1,"-27.22"]],[[0,"2021\u5e74\u62a5"],[1,"2022\u4e00\u5b63\u62a5"]],""] 总资产报酬率(ROE) 单位：% 查看明细>>
稀释每股收益： -5.16丹麦克朗 [[[0,"-5.78"],[1,"-12.66"],[2,"-17.26"],[3,"-23.75"],[4,"-5.16"]],[[0,"2021\u4e00\u5b63\u62a5"],[1,"2021\u4e2d\u62a5"],[2,"2021\u4e09\u5b63\u62a5"],[3,"2021\u5e74\u62a5"],[4,"2022\u4e00\u5b63\u62a5"]],"\u4e39\u9ea6\u514b\u6717"] 稀释每股收益单位：丹麦克朗查看明细>>	营业收入： 1507.70万丹麦克朗同比增长164.32% [[[0,"570.40"],[1,"13214.50"],[2,"23855.20"],[3,"29256.70"],[4,"1507.70"]],[[0,"2021\u4e00\u5b63\u62a5"],[1,"2021\u4e2d\u62a5"],[2,"2021\u4e09\u5b63\u62a5"],[3,"2021\u5e74\u62a5"],[4,"2022\u4e00\u5b63\u62a5"]],"\u4e07\u4e39\u9ea6\u514b\u6717"] 营业收入单位：亿丹麦克朗查看明细>>	每股现金流： -7.27丹麦克朗 [[[0,"-8.48"],[1,"-15.98"],[2,"-21.20"],[3,"-27.78"],[4,"-7.27"]],[[0,"2021\u4e00\u5b63\u62a5"],[1,"2021\u4e2d\u62a5"],[2,"2021\u4e09\u5b63\u62a5"],[3,"2021\u5e74\u62a5"],[4,"2022\u4e00\u5b63\u62a5"]],"\u4e39\u9ea6\u514b\u6717"] 每股现金流单位：丹麦克朗查看明细>>	总资产收益率(ROA)： -11.41% [[[0,"-53.17"],[1,"-11.41"]],[[0,"2021\u5e74\u62a5"],[1,"2022\u4e00\u5b63\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为丹麦克朗

近期重要事件

2022-08-31	详情>> 股本变动：变动后总股本4653.04万股
2022-08-11	财报披露：美东时间 2022-08-11 盘后发布财报
2022-08-09	复牌提示： 2022-08-08 16:00:20 停牌，复牌日期 2022-08-08 16:35:00
2022-05-16	详情>> 业绩披露： 2022年一季报每股收益-5.16丹麦克朗,归母净利润-2.23亿丹麦克朗,同比去年增长7.99%
2022-04-05	详情>> 业绩披露： 2021年年报每股收益-23.75丹麦克朗,归母净利润-10.18亿丹麦克朗,同比去年增长-20.24%
2022-03-14	股东大会：将于2022-04-06召开股东大会会议内容 ▼▲ 1.Management’s report on the Company's activities during the past financial year 2.Approval of the audited Annual Report 2021 3.Resolution on the cover of loss in accordance with the approved Annual Report 2021 4.Election of members to the Board of Directors 5.Election of the auditor 6.Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares 7.Proposal from the Board of Directors to amend the Company's Remuneration Policy 8.Proposal from the Board of Directors to approve the Company's Remuneration Report 9.Proposal from the Board of Directors to approve the fees for the Board of Directors for the financial year 2022 10.Proposal from the Board of Directors to approve introducing an option under the existing authorization in Article 7.1 of the Articles of Association for the Board of Directors to increase the share capital by way of debt conversion and, subject to approval of agenda item (12), to include a total aggregate cap for the nominal capital increases which the Board of Directors may decide upon pursuant to Article 7.1 and the proposed new Article 8.13 11.Proposal from the Board of Directors to approve a new authorisation to issue warrants 12.Proposal from the Board of Directors to raise loans against issuance of convertible debt instruments 13.Any other business
2021-11-12	详情>> 业绩披露： 2021年三季报(累计)每股收益-17.26丹麦克朗,归母净利润-7.38亿丹麦克朗,同比去年增长-58.28%
2021-09-06	温馨提示：美股因劳工节，9月6日休市一天
2021-08-13	详情>> 业绩披露： 2021年中报每股收益-12.66丹麦克朗,归母净利润-5.39亿丹麦克朗,同比去年增长-126.84%
2021-05-12	详情>> 业绩披露： 2021年一季报每股收益-5.78丹麦克朗,归母净利润-2.42亿丹麦克朗,同比去年增长-34.91%
2021-03-18	详情>> 业绩披露： 2020年年报每股收益-22.07丹麦克朗,归母净利润-8.47亿丹麦克朗,同比去年增长-48.15%
2021-03-16	股东大会：将于2021-04-15召开股东大会会议内容 ▼▲ 1.Management’s report on the Company's activities during the past financial year 2.Approval of the audited Annual Report 2020 3.Resolution on the cover of loss in accordance with the approved Annual Report 2020 4.Election of members to the Board of Directors 5.Election of the auditor 6.Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares 7.Proposal from the Board of Directors to amend the Company's Remuneration Policy a.Adoption of a revised Remuneration Policy including proposed amendments relating to the remuneration of the Board of Directors and the Executive Management b.Adoption of a revised Remuneration Policy including proposed amendments relating to the remuneration of the Executive Management 8.Proposal from the Board of Directors to approve the Company's Remuneration Report 9.Proposal from the Board of Directors to approve the fees for the Board of Directors for the financial year 20212 a.Approval of fees for the Board of Directors for the financial year 2021 in accordance with the proposed new Remuneration Policy set forth in agenda item 7a b.Approval of fees for the Board of Directors for the financial year 2021 in accordance with the proposed new Remuneration Policy set forth in agenda item 7b 10.Proposal from the Board of Directors to approve a new authorization to increase the share capital of the Company by way of cash contribution without pre-emption rights for the Company's existing shareholders and at market price 11.Any other business
2020-03-13	股东大会：将于2020-04-02召开股东大会会议内容 ▼▲ 1.Management’s report on the Company's activities during the past financial year 2.Approval of the audited Annual Report 2019 3.Resolution on the cover of loss in accordance with the approved Annual Report 2019 4.Election of members to the Board of Directors 5.Election of the auditor 6.Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares 7.Proposal from the Board of Directors to approve the Company's Remuneration Policy 8.Proposal from the Board of Directors to approve the fees for the Board of Directors for the financial year 2020 9.Proposal from the Board of Directors to approve a new authorization to increase the share capital of the Company by way of cash contribution and without pre-emption rights for the Company's existing shareholders 10.Proposal from the Board of Directors to approve a new authorization to increase the share capital of the Company by way of contribution in kind and without pre-emption rights for the Company's existing shareholders 11.Proposal from the Board of Directors to approve a new authorization to increase the share capital of the Company by way of cash contribution, by contribution in kind or by debt conversion and with pre-emption rights for the Company's existing shareholders 12.Proposal from the Board of Directors to approve a new authorization to the Board of Directors to issue warrants 13.Any other business
2020-03-13	详情>> 业绩披露： 2019年年报每股收益-16.91丹麦克朗,归母净利润-5.72亿丹麦克朗,同比去年增长-198.32%
2019-03-15	详情>> 业绩披露： 2018年年报每股收益18.94丹麦克朗,归母净利润5.81亿丹麦克朗,同比去年增长313.49%
2019-03-12	股东大会：将于2019-04-04召开股东大会会议内容 ▼▲ (1)Management’s report on the Company’s activities during the past financial year (2)Approval of the audited Annual Report 2018 (3)Resolution on the distribution of profit or the cover of loss in accordance with the approved Annual Report 2018 (4)Election of members to the Board of Directors (5)Election of the auditor (6)Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares (7)Proposal from the Board of Directors to amend the Company’s Articles of Association, including amendment of section 13.3 to include the Board of Directors’ election of a Vice-Chairman and amendment of section 13.4 to reflect that the Vice-Chairman has a casting vote in the absence of the Chairman (8)Proposal from the Board of Directors to update the Company’s Overall Guidelines for incentive pay to the Executive Management (9)Proposal from the Board of Directors to update the Company’s Remuneration Policy (10)Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2019 (11)Any other business (12)Management’s report on the Company’s activities during the past financial year (13)Approval of the audited Annual Report 2018 (14)Resolution on the distribution of profit or the cover of loss in accordance with the approved Annual Report 2018 (15)Election of members to the Board of Directors (16)Election of the auditor (17)Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares (18)Proposal from the Board of Directors to amend the Company’s Articles of Association, including amendment of section 13.3 to include the Board of Directors’ election of a Vice-Chairman and amendment of section 13.4 to reflect that the Vice-Chairman has a casting vote in the absence of the Chairman (19)Proposal from the Board of Directors to update the Company’s Overall Guidelines for incentive pay to the Executive Management (20)Proposal from the Board of Directors to update the Company’s Remuneration Policy (21)Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2019 (22)Any other business
2018-03-22	股东大会：将于2018-04-19召开股东大会会议内容 ▼▲ 1.Management’s report on the Company’s activities during the past financial year 2.Approval of the audited Annual Report 2017 3.Resolution on the distribution of profit or the cover of loss in accordance with the approved Annual Report 2017 4.Election of members to the Board of Directors 5.Election of the auditor 6.Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares 7.Proposal from the Board of Directors to update the Company’s Remuneration Policy and the Overall Guidelines for Incentive pay to the Executive Management of Zealand Pharma A/S 8.Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2018 9.Proposal by the Board of Directors to dissolve the Shareholder Nomination Committee, including proposal to delete Section 15 of the Company’s Articles of Association 10.Proposal by the Board of Directors to amend the Company’s Articles of Association, including (i) amendment of Section 5.8 to reflect the CVR no. of Computershare A/S, (ii) deletion of expired paragraphs in Section 8.1, (iii) update of the name of the Danish Business Authority in Section 9.2 and 9.8, (iv) amendment of Section 9.16 to ensure consistency between the Danish and English version of this Section and (v) deletion of the used authorization on electronic communication in Section 12.5 and (vi) deletion of Section 13.3 regarding retirement age for members of the Board of Directors 11.Proposal from the Board of Directors to approve a new authorisation to increase the capital of the Company 12.Any other business
2018-03-13	详情>> 业绩披露： 2017年年报每股收益-9.77丹麦克朗,归母净利润-2.72亿丹麦克朗,同比去年增长-76.9%
2017-07-06	详情>> 业绩披露： 2016年年报每股收益-6.33丹麦克朗,归母净利润-1.54亿丹麦克朗,同比去年增长-35.06%

主营业务分析

注：通常在中报、年报时披露　

项目名称		营业收入(万丹麦克朗)	收入比例(%)
按业务	许可费和里程碑	1095.6	72.67
按业务	商品销售	412.1	27.33

项目名称		营业收入(万丹麦克朗)	收入比例(%)
按业务	商品销售	18402.1	62.90
按业务	许可费和里程碑	10854.6	37.10

项目名称		营业收入(万丹麦克朗)	收入比例(%)
按业务	商品销售	14334.8	60.09
按业务	许可费和里程碑	9520.4	39.91

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。